pharma · Ulcerative Colitis · Diabetes Mellitus, Type 2
Eli Lilly and
Eli Lilly and Company
Eli Lilly and clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Employees
- 55,860
- Programs
- 62
- Drugs
- 42
- Patents
- 0
Eli Lilly and projects
8 ClinicalTrials.gov programs sponsored by Eli Lilly and.
Eli Lilly and has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Donanemab
Eli Lilly and Company
Cognitive Dysfunction
1 trial -
Eltrekibart
Eli Lilly and Company
Ulcerative Colitis
1 trial -
LY2157299
Eli Lilly and Company
Carcinoma, Hepatocellular
1 trial -
LY3454738
Eli Lilly and Company
Atopic Dermatitis
1 trial -
LY4268989
Eli Lilly and Company
Ulcerative Colitis (UC)
1 trial -
Mirikizumab - Intravenous (IV)
Eli Lilly and Company
Colitis, Ulcerative
1 trial -
Ramucirumab
Eli Lilly and Company
Gastric Adenocarcinoma
1 trial -
Selpercatinib
Eli Lilly and Company
Medullary Thyroid Cancer
1 trial
Frequently asked questions
How many clinical projects does Eli Lilly and have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.